drugset

Drugs / VR588

Follow last change Nov 2020 re-read 3 minutes ago

VR588

Developed for: asthma
Investigated by: Imperial College London · Vectura Limited

Trials 1

today NCT02740049 · Ph 0

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT02740049	Jan → Oct 2016	asthma	Imperial College London	Completed	Mixed

Press releases naming this drug 1 release

Date	Issuer	Release
2020-11-30	Kinaset Therapeutics Inc	Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory kinasettherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VR588	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02740049 ↗
Action	Inhibit	“a novel JAK/STAT inhibitor, VR588” NCT02740049 ↗